Summary:
The study consists of a 12-15 week treatment period, with an inpatient portion lasting up to 14 days followed by 8 weekly follow up visits. The purpose of this study is to evaluate the efficacy and safety of intramuscular injections of Risperidone in patients with acute exacerbation of Schizophrenia.
Qualified Participants Must:
• Ages 18-65 with a BMI of 18.5-40
•
Willing to stay inpatient in our clinical research unit (stay not to exceed 14 days)
•
Diagnosis of Schizophrenia with current acute exacerbation
•
Never Bipolar or Schizoaffective
•
Good physical health
•
No seizure disorder, strokes or tumor
•
Hospitalized no more than 30 days within the last 90 days
Qualified Participants May Receive:
Potential stipend of $1,050 for completion of study.